Document is current
Any future updates will be listed below
-
Authors
Mohty, Razan
Reljic, Tea https://orcid.org/0000-0003-2029-6753
Abdel-Razeq, Nayef
Jamy, Omer
Badar, Talha https://orcid.org/0000-0003-1548-918X
Kumar, Ambuj
Aljurf, Mahmoud https://orcid.org/0000-0003-3942-7370
Kharfan-Dabaja, Mohamed A. https://orcid.org/0000-0001-7394-5185
- License Information
-
More Information
Article History
Received: 10 June 2024
Revised: 11 July 2024
Accepted: 15 July 2024
First Online: 26 July 2024
Competing interests
: RM, TR, NA-R, TB, AK and MA report no relevant conflicts of interest. OJ reports advisory board participation for Ascentage pharma. MAK-D reports research/grant support from Bristol Myers Squibb, Novartis and Pharmacyclics; Lecture/Honoraria from Kite Pharma.
